Mobia Medical, Inc.
BioSniper AI · MOBI
Mobia Medical, Inc. is a commercial-stage medical device company focused on stroke recovery through its Vivistim Paired VNS system, which recently received a favorable CMS proposed payment rate for 2027.
Key risk: Reimbursement dependency
Spotter reads the filings and answers with citations.
BioSniper Score
Based on 4 of 6 signals
Tracking 1 pipeline candidate for Mobia Medical, Inc. · Updated within the last hour.
Mobia Medical, Inc. is a commercial-stage medical device company focused on stroke recovery through its Vivistim Paired VNS system, which recently received a favorable CMS proposed payment rate for 2027.
- Mobia Medical is a commercial-stage medical device company redefining stroke recovery for survivors with motor impairments [news · 2026-07-02].
- CMS proposed to maintain CPT Code 64568 under New Technology APC 1580 for CY 2027 with an outpatient payment rate of approximately $45,000 [news · 2026-07-02].
- The company completed an IPO on May 7, 2026, pricing 10,000,000 shares at $15.00 per share, raising gross proceeds before deductions [news · 2026-05-08].
- Insider transactions post-IPO include purchases by executives and major shareholders at $15.00 per share [insider_transaction · 2026-05-11].
- Analyst coverage initiated with target prices ranging from $16 to $31 [news · 2026-06-02].
What works
- CMS proposed to maintain Vivistim's procedure code under New Technology APC 1580 with a ~$45,000 payment rate for 2027, supporting reimbursement stability [news · 2026-07-02].
- The company successfully completed an IPO raising significant capital, indicating investor interest [news · 2026-05-08].
- Insider purchases post-IPO by executives and major shareholders at $15.00 per share suggest internal confidence [insider_transaction · 2026-05-11].
- Analyst coverage initiation with bullish notes and target prices up to $31 reflects positive market sentiment [news · 2026-06-02].
What to weigh
- The company's stock had a tough debut post-IPO, with analysts remaining on the sidelines [news · 2026-05-10].
- As a commercial-stage company, Mobia Medical faces the challenge of achieving widespread adoption and revenue growth in a competitive stroke recovery market [news · 2026-05-10].
- The company's reliance on CMS reimbursement decisions introduces regulatory risk, though the current proposal is favorable [news · 2026-07-02].
- Insider transactions include significant stock conversions and option exercises at $0.00, which may dilute existing shareholders [insider_transaction · 2026-05-11].
From the filings
Quoted directly from source documents.
CMS proposed to maintain Vivistim procedure code under New Technology APC 1580 for 2027
“the Centers for Medicare and Medicaid Services (CMS) has proposed to maintain CPT® Code 64568, the procedure code used for the Vivistim® procedure, under the New Technology Ambulatory Payment Classification (APC) 1580 for calendar year (CY) 2027”
News · July 2, 2026
IPO pricing of 10,000,000 shares at $15.00 per share
“pricing of its initial public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share”
News · May 8, 2026
Analyst target prices for MOBI stock range from $16 to $31
“MOBI target prices: $16, $19, $31”
News · June 2, 2026
Insider purchases at $15.00 per share post-IPO
“HARRINGTON WILLIAM T (N/A) P 266667 shares @ $15.00 on 2026-05-11”
Insider filings · May 11, 2026
Risks & what to watch (4)›
Key risks
- Reimbursement dependency — Revenue relies on CMS maintaining favorable payment rates; any adverse change could impact adoption [news · 2026-07-02].
- Commercial-stage execution — As a newly public commercial-stage company, scaling sales and market penetration is unproven [news · 2026-05-10].
- Stock dilution from insider conversions — Significant insider stock conversions at $0.00 may dilute existing shareholders [insider_transaction · 2026-05-11].
- Competitive stroke recovery market — The stroke recovery market is crowded with alternative therapies, posing adoption challenges [news · 2026-05-10].
What to watch
- Final CMS rule for CY 2027 Hospital Outpatient Prospective Payment System, expected later in 2026 [news · 2026-07-02].
- Quarterly revenue and adoption metrics for Vivistim post-IPO [news · 2026-05-08].
- Insider trading activity and any secondary offerings [insider_transaction · 2026-05-11].
- Analyst rating changes and price target adjustments [news · 2026-06-02].
Sources: Insider filings · News · PubMed · Generated July 14, 2026 · How we verify sources →
Unlock the full Mobia Medical, Inc. dossier
Sign in free to see catalysts, full pipeline, financials, FDA decisions, news, and run live AI deep-dives.
Free account includes:
- Full pipeline, catalysts, financials & FDA decisions for Mobia Medical, Inc.
- 200 free AI credits / month to run live Spotter deep-dives
- Watchlist, news alerts & the biotech event calendar
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
10.2 months
OCF -$18M · Net income -$18M
No tracked pipeline phase
1 candidate
No upcoming catalysts tracked
12 buys · 1 sell (180d)
Runway
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for Mobia Medical, Inc.?
Mobia Medical, Inc. is a commercial-stage medical device company focused on stroke recovery through its Vivistim Paired VNS system, which recently received a favorable CMS proposed payment rate for 2027.
Who is the CEO of Mobia Medical, Inc.?
Mr. Richard John Foust is the chief executive officer of Mobia Medical, Inc. (MOBI).
Where is Mobia Medical, Inc. headquartered?
Mobia Medical, Inc. (MOBI) is headquartered in Austin, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on Mobia Medical, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.